Table 4.
Comparison of number of re-genome biopsies in the first and second half of the analysis period
| Sampling method | First half year Jan.2019-Dec.2020 |
Second half year Jan.2021-Nov.2022 |
Total cases (%) | P value |
|---|---|---|---|---|
| TBB + EBUS-TBNA (n) | 176 | 194 | 370 | |
| TBB (n) | 126 | 110 | 236 | |
| EBUS-TBNA (n) | 50 | 84 | 134 | |
| Rebiopsy in TBB + EBUS-TBNA (%) | 22 (12.5) | 11 (5.7) | 33 (8.9) | P = 0.0276* |
| Rebiopsy in TBB (%) | 18 (14.3) | 6 (5.5) | 24 (10.2) | P = 0.0305* |
| Rebiopsy in EBUS-TBNA (%) | 4 (8.0) | 5 (6.0) | 9 (6.7) | P = 0.727 |
TBB transbronchial biopsy, EBUS-TBNA Endobronchial ultrasound-guided transbronchial needle aspiration
*indicates statistical significance